Stock Events

Verve Therapeutics 

$5.51
49
+$0.12+2.23% Wednesday 20:00

Statistics

Day High
5.95
Day Low
5.28
52W High
20.12
52W Low
4.31
Volume
1,618,492
Avg. Volume
1,455,164
Mkt Cap
566.98M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

5
NOV
Earnings
 

Earnings

5NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-0.92
-0.62
-0.31
0
Expected EPS
-0.683609
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VERV. It's not an investment recommendation.
Alphabet
73648
GOOGL
Apple
64217
AAPL
Microsoft
59917
MSFT
Amazon
55249
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics is a leading competitor in the CRISPR/Cas9 gene editing technology, directly competing with Verve's gene-editing approaches for cardiovascular diseases.
Editas Medicine
EDIT
Mkt Cap308.46M
Editas Medicine operates in the gene editing sector focusing on developing therapies to treat genetically driven diseases, similar to Verve's focus on cardiovascular diseases.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is at the forefront of developing gene-based medicines for serious diseases, including cardiovascular, which competes with Verve's pipeline.
Beam Therapeutics
BEAM
Mkt Cap2.2B
Beam Therapeutics uses base editing, a form of gene editing, for genetic diseases, competing with Verve's gene editing therapies for cardiovascular conditions.
Sangamo Therapeutics
SGMO
Mkt Cap176.57M
Sangamo Therapeutics focuses on genomic medicines, including gene editing, competing in the same space as Verve with a focus on cardiovascular diseases.
Bluebird bio
BLUE
Mkt Cap108.22M
Bluebird bio focuses on gene therapies for severe genetic diseases and cancer, indirectly competing with Verve's gene editing approach for cardiovascular diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap33.72B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, which could compete with Verve's gene editing therapies in treating cardiovascular diseases.
Ionis Pharmaceuticals
IONS
Mkt Cap6.97B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, offering a competitive approach to Verve's gene editing strategies for cardiovascular diseases.
Voyager Therapeutics
VYGR
Mkt Cap357.74M
Voyager Therapeutics focuses on developing gene therapies for severe neurological diseases, representing indirect competition in the broader gene therapy market.
Adverum Biotechnologies
ADVM
Mkt Cap144.36M
Adverum Biotechnologies develops gene therapy approaches for ocular and rare diseases, competing in the gene therapy space with potential applications in cardiovascular diseases.

Analyst Ratings

26$Average Price Target
The highest estimate is $40.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Employees
255
Country
US
ISIN
US92539P1012

Listings

XNAS
US
VERV